ICBS enters billion dollar scientific environmental market, acquires 25% interest in BioSpec Global Solutions Inc.

NEW YORK, MONTREAL, July 9 – ICBS Ltd. (OTCPK: ICBT), announced today that it has entered into an agreement to acquired Twenty five percent interest in BioSpec Global Solutions Inc., who has developed state-of-the-art technologies for rapid, onsite (remote) monitoring of microbial contamination in drinking water, recreational water, agriculture & food production, pharmaceuticals and medical applications.

TOGS(TM) 9000 instrument is a single test, precision, portable incubator utilizing the patented technology provide on-site testing of microbial contamination in drinking water. Used in conjunction with a chromogenic reagent, it provides an accurate, virtually fool-proof microbial test for field, rural and remote applications in the detection of Total Coliforms and E.coli to WHO standards using globally approved methods (USEPA, AWWA-APHA). This bio-photonic incubation/detection instrument can be electronically sent to an appropriate laboratory and or regulatory authority in a secure monitoring system using “AGACSS(TM)” software and the internet, is revolutionary and its market global.

The TOGS(TM) 9000 instrument also eliminates the many false positives that result from loss of sample integrity caused by transporting, handling and hold time errors. Present day testing methods are laboratory confined, take days to do, and are sometimes inaccurate, labor intensive and costly. TOGS(TM) 9000 instrument can provide a complete analysis within 10 hours.

Worldwide, over a billion water, food, environmental, pharmaceutical and clinical samples are sent to laboratories for microbial testing each year. That market is growing dramatically, fostered in the last few years by concerns about our food and water safety, spread of disease and pandemics, antibiotic resistant microbes, hospital transmitted infections, and bio-terrorism.

“We are very excited about our partnership with BioSpec Global Solutions” announced Garth McIntosh, President and CEO of ICBS, “we are always on the look out for new and exciting opportunities and we believe that the partnership with BioSpec will continue our focus in the medical such as Canadian Bio Med Systems.”

NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company’s disclosure documents.

SOURCE Inter Canadian Business Service